NCT03898856View on ClinicalTrials.gov

Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea in Non-HIV Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions
Chronic Diarrhea of Unknown Origin
Interventions
DRUG

Crofelemer

125 mg tablets taken by mouth twice daily for 28 days

DIAGNOSTIC_TEST

Diagnostic tests for cause of chronic diarrhea

Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

Sponsors
All Listed Sponsors
collaborator

Napo Pharmaceuticals, Inc.

INDUSTRY

lead

The University of Texas Health Science Center, Houston

OTHER

NCT03898856 - Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea in Non-HIV Patients | Biotech Hunter | Biotech Hunter